Authors’ contributions RF participated in design of the study, SGC-CBP30 order carried out molecular studies, drafted manuscript and performed statistical analysis. SH participated in design of the study and reviewed manuscript. ZG and ZR carried out immunohistochemistry and western blotting analysis. All authors read and approved the final manuscript.”
“Background MicroRNAs (miRNAs) are short noncoding ribonucleic acid (RNA) molecules, approximately 22-nucleotide
long, Selleckchem ON-01910 and single-stranded [1]. MiRNAs are post-transcriptional regulators that bind to complementary sequences on target messenger RNA transcripts (mRNAs), usually resulting in translational repression or target degradation and gene silencing, thereby modulating a variety of biological process such as cell growth, proliferation, differentiation, metabolism, and apoptosis [2–4]. Some miRNAs are reported to be associated with clinical outcomes in some tumors, such as blood carcinomas [5, 6], lung cancer [7, 8], pancreatic BIIB057 cancer [9, 10], and colon adenocarcinoma [11, 12]. Glioblastoma (GBM, WHO grade IV glioma) is the most malignant brain tumor in adults. Even after treatment with surgical resection and radiotherapy plus concomitant chemotherapy, most patients with the diagnosis of GBM seldom survive more than 15 months [13]. A
number of molecular markers for GBM associated with diagnosis, prognosis, and treatment have been identified. Somatic mutations in IDH1 have been identified in GBM patients, especially in
secondary GBM which evolves from lower-grade gliomas [14]. Several miRNA signatures associated with IDH1 mutations have been revealed via miRNA expression profiling and better outcomes have been predicted for GBM patients with IDH1 mutations [1]. However, to date, no valuable prognostic miRNA signatures have been reported for patients with wild-type IDH1 GBM. In the present study, we used the GBM miRNA dataset from The Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov/) and selected miRNAs that were differentially expressed between wild-type and mutant-type IDH1 GBM samples. As a result, we successfully identified a 23-miRNA signature, which predicted a better outcome for GBM patients with wild-type IDH1. Methods and materials Samples MiRNA expression Anacetrapib data (level 3) and the corresponding survival data for glioblastoma samples were downloaded from The Cancer Genome Atlas (TCGA) data portal. Two mutant-type IDH1 samples and 30 wild-type IDH1 samples were removed during analysis because of unavailable survival information or very short survival time (less than 30 days, probably caused by other lethal factors). Thus, a total of 155 GBM patients, with 15 mutant-type and 140 wild-type IDH1 patients, were enrolled for further analysis. Because the data were obtained from TCGA, further approval by an ethics committee was not required.